Case Preview · Custom Portal

<div id="overviewDiv" class="divsummary"><span class="divheading">Overview</span><div class="tableddiv"><table class="tablesummary"><tr><th>Case Number</th><th>Received Date</th><th>Finalised Date</th><th>Product/s</th><th>Responsible Person</th></tr><tr><td>CC-I66ACDFN/2020*</td><td>17/03/2020</td><td>30/10/2021</td><td><ul><li>ABUNDANT NATURAL HEALTH  MAGNESIUM GEL</li><li>ABUNDANT NATURAL HEALTH MAGNESIUM SPRAY</li><li>ABUNDANT NATURAL HEALTH MAGNESIUM GEL</li><li>ABUNDANT NATURAL HEALTH MAGNESIUM SPRAY</li></ul></td><td><ul><li>Abundant Natural Health</li></ul></td></tr></table></div></div><div id="summaryDiv" class="divsummary"><span class="divheading">Case Summary</span><div class="tableddiv"><span class="divheadingtwo">Alleged Breaches</span><div id="allegationAdvertisingTherapeutic Goods Act 1989" class="divadvertisingcode"><span class="allegationtype"><a href="https://www.legislation.gov.au/Series/C2004A03952" target="_blank">Therapeutic Goods Act 1989</a></span><ul><li>s42DL(7)(a) - Advertisement contains a restricted representation and neither an approval under section 42DF nor a permission under section 42DK is in force in relation to the restricted representation</li><li>s42DLB(4)(a) - Advertisement contains a restricted representation and neither an approval under section 42DF nor a permission under section 42DK is in force in relation to the restricted representation</li></ul></div><span class="divheadingtwo">Summary</span><div class="breachDiv"><div data-wrapper="true" style="font-size:9pt;font-family:'Segoe UI','Helvetica Neue',sans-serif;">
<div>The TGA received a complaint in relation to an email, which was forwarded to customers claiming that Abundant Natural Health’s product, hand disinfectant was effective against COVID-19.&nbsp;</div>

<div><br>
The TGA considered that the advertisement contained a restricted representation because it referred to a serious form of disease, being COVID-19. This representation had not been approved by the Secretary of the Department of Health and, accordingly, the advertisement containing the restricted representation breached s 42DL(3) of the Therapeutic Goods Act 1989 (Cth) (Act), where s 42DL(7)(a) applied, and s 42DLB(1) of the Act, where s 42DLB(4)(a) applied.&nbsp;</div>

<div><br>
These advertisements were of concern to the TGA given the current pandemic.<br>
&nbsp;</div>
</div></div></div></div><div id="actionsDiv" class="divsummary"><span class="divheading">Actions</span><div class="tableddiv"><table class="tablesummary"><tr><th>Date</th><th>Action</th><th> </th></tr><tr><td>18/03/2020</td><td>Warning Letter requiring action sent to advertiser</td><td>The TGA advised the sponsor of the alleged breaches contained in the email sent to customers. <br><br></td></tr></table></div></div><div id="outcomeDiv" class="divsummary"><span class="divheading">Case Outcome</span><div class="tableddiv"><table class="tablesummary"><tr><th>Date</th><th>Case Outcome</th><th> </th></tr><tr><td>28/10/2020</td><td>Case resolved</td><td>The Advertiser issued a retraction statement to their e-mail subscribers.</td></tr></table></div></div><div id="previewDiv"></div>
NoYes